Article in NPJ systems biology and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jenna L BallardGraduate Group in Genomics and Computational Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Zongyu DaiGraduate Group in Applied Mathematics and Computational Science, University of Pennsylvania, Philadelphia, PA, USA.
Li ShenDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. li.shen@pennmedicine.upenn.edu.
Qi LongDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. qlong@pennmedicine.upenn.edu.
Funding
Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse CohortsU19AG074879 · NIA · MAYO CLINIC JACKSONVILLE · PI Minerva Maria Carrasquillo, NILUFER ERTEKIN-TANER · 2023 to 2026
$42.0M
Ultrascale Machine Learning to Empower Discovery in Alzheimers Disease BiobanksU01AG068057 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Christos Davatzikos, Heng Huang · 2020 to 2026
$20.7M
Artificial Intelligence Strategies for Alzheimer's Disease ResearchU01AG066833 · NIA · CEDARS-SINAI MEDICAL CENTER · PI MOORE, JASON H., RITCHIE, MARYLYN D · 2022 to 2025
$6.7M
Metabolic Signatures Underlying Vascular Risk Factors for Alzheimer-type DementiasRF1AG051550 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KLING, MITCHEL ALLAN · 2015 to 2016
$6.3M
Metabolic Networks and Pathways in Alzheimer's DiseaseR01AG046171 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F · 2014 to 2017
$4.4M
Translational big data analytic approaches to advance drug repurposing for Alzheimer's diseaseR01AG071470 · NIA · UNIVERSITY OF PENNSYLVANIA · PI KIM, DOKYOON, NING, XIA · 2021 to 2025
$3.8M
Advancing Analysis of Multi-omics Data in Alzheimer's Disease ResearchRF1AG063481 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LONG, QI · 2019 to 2020
$3.8M
Statistical Modeling of Alzheimer's Disease Progression Integrating Brain Imaging and -Omics DataR01AG071174 · NIA · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KUNDU, SUPRATEEK, LONG, QI · 2021 to 2025
$3.3M
Robust privacy preserving distributed analysis platform for cancer research: addressing data bias and disparitiesU01CA274576 · NCI · UNIVERSITY OF PENNSYLVANIA · PI JIANG, XIAOQIAN, LONG, QI · 2023 to 2025
Integrative analysis of multi-omics data provides a more comprehensive and nuanced view of a subject's biological state. However, high-dimensionality and ubiquitous modality missingness present significant analytical challenges. Existing methods for incomplete multi-omics data are scarce, do not fully leverage both modality-specific and shared information, and produce task-biased representations. We propose JASMINE, a self-supervised representation learning method for incomplete multi-omics data that preserves both modality-specific and joint information and enhances sample similarity structure. JASMINE produces embeddings that achieve superior performance across multiple tasks for two different incomplete multi-omics datasets while requiring only a single round of training per dataset.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A powerful representation learning method for enhanced analysis of incomplete multi-omics data. · full record | OpenQuestion